Presentations online

Plenary session 1: Opening ceremony

O01. NDDO Honorary Award Lecture 2010:
GENETIC DETERMINANTS AS BASIS FOR TARGETED CANCER THERAPIES: FROM TRASTUZUMAB TO SUNITINIB AND FURTHER… Axel Ullrich, Martinsried, Germany

O02. Keynote Lecture: SYSTEMS BIOLOGY APPROACH TO PERSONALIZED MEDICINE. Gordon B. Mills, Houston, TX

Plenary session 2: Insulin-like growth factor receptor inhibitors

O03. Educational Lecture: BIOLOGY OF THE INSULIN-LIKE GROWTH FACTORS. Douglas Yee, Minneapolis, MN 

O04. IGF1R INHIBITORS: RATIONAL COMBINATORIAL STRATEGIES. Valentine Macaulay, Oxford, United Kingdom

O05. BIOMARKERS OF THE SAFETY AND EFFICACY OF FIGITUMUMAB (CP-751,871).
Jean-Charles Soria, Villejuif, France

O06.TARGETING TYPE I INSULIN-LIKE GROWTH FACTOR RECEPTOR AND INSULIN RECEPTOR FOR CANCER THERAPY: THE ORAL DUAL INHIBITOR BMS-754807 IN CLINICAL DEVELOPMENT. Jayesh Desai, Melbourne, Australia

O07. OSI-906: A DUAL IGF-1R/IR INHIBITOR FOR THE TREATMENT OF CANCER. Elizabeth Buck, Farmingdale, NY

Plenary session 3: Cancer stem cell targets

O08. Educational Lecture: STEM CELLS IN SOLID TUMORS. Percy Ivy, Bethesda, MD

O09. HEDGEHOG-TARGETING AGENTS. Kyriakos Papadopoulos, San Antonio, TX

O10. NOTCH-TARGETING AGENTS. Patricia LoRusso, Detroit, MI

O11. TARGETING WNT SIGNALING IN CANCER STEM CELLS; A TALE OF TWO COACTIVATORS. Michael Kahn, Los Angeles, CA

Plenary session 4: Cell signaling targets

O12. SGI-1776, A NOVEL PIM KINASE INHIBITOR, FOR THE TREATMENT OF CANCER. Sven de Vos, Los Angeles, CA

O13. DEVELOPMENT OF JAK INHIBITORS FOR THE TREATMENT OF HUMAN  NEOPLASMS. Adrian Senderowicz, Wilmington, DE

O14. PAK4, A NOVEL ANTICANCER TARGET. Gail Eckhardt, Aurora, CO.

O15. RAF INHIBITION AND SKIN NEOPLASIA INDUCTION.. Caroline Robert, Villejuif, France  

O16. FIRST-IN-HUMAN, SAFETY, PHARMACODYNAMIC (PD) AND PHARMACOKINETIC (PK) TRIAL OF A FIRST-IN-CLASS DUAL RAF/MEK INHIBITOR, RO5126766, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMOR. Maria Martinez Garcia, Barcelona, Spain

O17. DEVELOPMENT OF MEK INHIBITORS FOR ONCOLOGY. Jim Winkler, Boulder, CO

Plenary session 5: RNA-based approaches

O19. MANIPULATING MICRO-RNA FOR CANCER THERAPY: PROBLEMS AND PERSPECTIVES. Cristiana Sessa, Bellinzona, Switzerland

O20. IDENTIFYING CANCER CELL VULNERABILITY WITH SYNTHETIC LETHAL RNAI SCREEN. Ji Luo, Bethesda, MD

Plenary session 6: Tumor microenvironment

O21. Keynote Lecture: MICROENVIRONMENTAL INFLUENCES ON CANCER STEM CELLS
Lee Ellis, Houston, TX

Plenary session 7: Drugs targeting DNA repair mechanisms

O22. Educational Lecture: MECHANISMS OF DNA DAMAGE AND REPAIR. Ruth Plummer, Newcastle, United Kingdom

O23. PARP INHIBITORS IN CLINICAL DEVELOPMENT - AN OVERVIEW. Hilary Calvert, London, United Kingdom

PP01. A PHASE I COMBINATION STUDY OF OLAPARIB (AZD2281; KU-0059436) AND CISPLATIN (C) PLUS GEMCITABINE (G) IN ADULTS WITH SOLID TUMORS. Arun Rajan, Bethesda, MD

PP02. THE TREATMENT OF PANCREATIC CANCER WITH POLY(ADP-RIBOSE) POLYMERASE INHIBITORS ALONE OR IN COMBINATION WITH STANDARD CHEMOTHERAPY. Joseph de Soto, Bethesda, MD.

O24. RAD 51 AS A NOVEL TARGET IN SOLID TUMORS. Anthony Tolcher, San Antonio, TX

PP03. ATM AND/OR DNA-PK FACILITATES REPAIR OF TOPOISOMERASE I-ASSOCIATED BREAKS BY NOVEL PHOSPHORYLATION OF THE DNA REPAIR ENZYME TDP1 AT SER81. Benu Brata Das, Bethesda, MD

Plenary session 8: Drug development methodology & regulatory affairs

O25. PREDICTIVE BIOMARKERS: REGULATORY POINT OF VIEW. Robert Becker, Rockville, MD

O26. Report MDICT Task Force Meeting, March 3. Targeted agents: How to select the winners in preclinical and early clinical studies?  Elizabeth Eisenhauer, Kingston, ON, Canada

MINI-SYMPOSIUM: DISAPPOINTING PHASE 3 OUTCOMES AFTER PROMISING RANDOMIZED PHASE 2 STUDIES; WHAT WENT WRONG?

O27. VANDETANIB FOR NSCLC. John Wright, Bethesda, MD
O28. AXITINIB FOR PANCREATIC CANCER. Austin Duffy, Bethesda, MD
O29. PHASE 2 TRIALS IN ONCOLOGY: WHAT REALLY MATTERS? Steven Averbuch, Princeton, NJ

Plenary session 9: Tyrosine kinase drug targets

O30. TARGETING THE MET ONCOGENE BY ANTIBODIES AND/OR SMALL MOLECULE INHIBITORS. Paolo Comoglio, Turin, Italy

O31. CLINICAL EVALUATION OF THE SELECTIVE C-MET INHIBITOR ARQ 197 AS A PARADIGMATIC MODEL FOR HIGHLY TARGETED ANTI-CANCER DRUG DEVELOPMENT. Edward Garmey, Woburn, MA

PP04. A CHEMICALLY STABILIZED, CHIMERIC MONOVALENT ANTI-MET ANTIBODY INHIBITS MET-DEPENDENT TUMOR GROWTH BY PROMOTING RECEPTOR SHEDDING AND PROTEASOME-MEDIATED DEGRADATION. Paolo Michieli, Turin, Italy

O36. TARGETING PI3-KINASE-AKT: COMPLEXITIES AND POTENTIAL STRATEGIES. Alex Adjei, Buffalo, NY

O32. JAK2 INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS. Ayalew Tefferi, Rochester, MN

O33. ALK GENE REARRANGEMENTS AND THE DEVELOPMENT OF PF-02341066 IN NSCLC. D. Ross Camidge, Aurora, CO

Plenary session 10: Miscellaneous targets

O34. HSP90 AND CANCER: TARGETING A DYNAMIC CHAPERONE COMPLEX. Len Neckers, Bethesda, MD

PP06. A PHASE 1 STUDY OF PF-04929113 (SNX5422), AN ORALLY BIOAVAILABLE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR AFTER TWICE WEEKLY ADMINISTRATION IN PATIENTS WITH REFRACTORY SOLID TUMOR MALIGNANCIES AND LYMPHOMA. Giuseppe Giaccone,, Bethesda, MD.

O35. AN EMT BIOMARKER IN NON-SMALL CELL LUNG CANCER (NSCLC) PREDICTS CLINICAL BENEFIT FROM ERLOTINIB THERAPY. David Sternberg, Farmingdale, NY

O37. EARLY DEVELOPMENT OF AN ANTI-EPIDERMAL GROWTH FACTOR-LIKE DOMAIN 7 (ANTI-EGFL7) HUMANIZED ANTIBODY: PRECLINICAL TO CLINICAL CORRELATES. Louie Naumovski, South San Francisco, CA

PP07. NOVEL MULTIPLEX PI3-KINASE INHIBITORS POTENTLY INHIBIT RAS-MUTATED TUMORS VIA SUPPRESSION OF EIF-4E-MEDIATED PROTEIN TRANSLATION. Dapeng Qian, Tarrytown, NY

PP05. AC220, A POTENT, SELECTIVE, SECOND GENERATION FLT3 RECEPTOR TYROSINE KINASE INHIBITOR, IN A FIRST-IN-HUMAN PHASE 1 AML STUDY. Mohit Trikha, San Diego, CA

Plenary session 11: Apoptotic and nuclear targets

O38. BCL-2 FAMILY PROTEIN INHIBITORS. Andrew Krivoshik, Abbott Park, Ill, USA

O39. DEVELOPMENT OF MAPATUMUMAB, A FULLY HUMAN AGONISTIC MONOCLONAL ANTIBODY WHICH TARGETS AND ACTIVATES THE TRAIL-RECEPTOR-1. Gilles Gallant, Rockville, MD

O40. HDAC INHIBITORS IN LYMPHOMAS AND SOLID TUMORS: THINKING ABOUT DRUG RESISTANCE. Susan Bates, Bethesda, MD

PP08. THE APOPTOTIC RING: A NOVEL ENTITY WITH PHOSPHORYLATED HISTONES H2AX AND H2B, AND ACTIVATED DNA DAMAGE RESPONSE KINASES. Stéphanie Solier, Bethesda, MD

PP09. TELOMERASE-PEPTIDE VACCINE TOGETHER WITH GEMCITABINE IN ADVANCED PANCREATIC CANCER PATIENTS. Caroline Staff, Stockholm, Sweden

Plenary session 12: Cell cycle targets

O41. Educational Lecture: THE CELL DIVISION MACHINERY AS ANTI-CANCER DRUG TARGET. Susanne Lens, Utrecht, The Netherlands

O42. AURORA AND POLO-LIKE KINASE INHIBITORS: A CLINICAL PERSPECTIVE. Ahmad Awada, Brussels, Belgium

O43. DANUSERTIB, A PAN-AURORA KINASE INHIBITOR: CLINICAL REVIEW. Bernard Laffranchi, Milan, Italy

O44. PRECLINICAL AND CLINICAL DEVELOPMENT OF CYCLIN-DEPENDENT KINASE AND CHECKPOINT KINASE INHIBITORS. Geoffry Shapiro, Boston, MA